精制去纤酶治疗脑梗塞30例临床效果观察

Purified difibrinogenase in treatment of cerebral infarction: Clinical and therapeutic observations of 30 cases

采用蜀阳生产的精制去纤酶治疗脑梗塞患者３０例，综合神经功能缺损程度及生活能力状态级别来评价临床总的疗效，结果表明：基本痊愈达２０％，显著进步率４３．３３％，进步率３０％，总有效率达９３．３３％。而用低分子右旋糖酐加复方丹参治疗１５例脑梗塞，总有效率仅为４６．４７％，两组相比较差异有显著性（Ｐ＜０．０１）。精制去纤酶治疗脑梗塞前后血液流变学中的全血低切粘度、红细胞聚集性及血液还原粘度、血浆纤维蛋白原，用ｔ检验，差异均有显著性（Ｐ＜０．０５），而血浆粘度、全血高切粘度也有下降趋势。但在统计学上无意义，精制去纤酶对血小板计数、出凝血时间、肝肾功能无影响，到目前为止，未发现有出血、过敏及其它的不良反应，故认为精制去纤酶治疗脑梗塞与低分子右旋糖酐加复方丹参相比，具有作用快、疗程短、疗效显著的特点，值得进一步研究应用。

?0 cases of cerebral infarction were treated with purified difibringenase made in Shuyang. The total clinical and therapeutic effectiveness was evaluated with defective degrees of neural function and grades of viability. Results showed that basic cure rate reached 20%, significantly progressive rate 43.33% and progressive rate 30%. The total effectiveness rate was 93.33%. But the total effectiveness rate was only 46.47% in 15 cases of cerebral infarction treated with low molecular dextran plus compound saliva miltiorrhiza. The difference was highly significant between two groups(P<0.01). The difference was significant(P<0.05) with t test in low incisal viscosity of whole blood, sympexis and blood reductive viscosity and plasma fibrinogen of blood rheology before and after treatment with purified difibrinogenase while plasma viscosity and high incisal viscosity of whole blood had a descending tendency. It had no meaning statistically. Purified difibrinogenase did not affect platelet count, bleeding and coagulation time, liver and renal function. Up to now, no adverse reactions such as hemorrhage, allergy and others have been found. It is thought that purified difibrinogenase has quicker and more effective characteristics and shorter treatment course than low molecular dextran plus compound saliva miltiorrhiza in treating cerebral infarction. 